GHRP-6 vs Ipamorelin

Ghrelin receptor agonist; stimulates pituitary GH release and increases appetite via hypothalamic ghrelin pathways

GHRP-6 (growth hormone-releasing peptide 6) is a synthetic hexapeptide GH secretagogue that acts as an agonist at the ghrelin receptor (GHS-R1a) in pituitary somatotrophs and the hypothalamus, stimulating GH release through a mechanism that is synergistic with but distinct from endogenous growth hormone-releasing hormone (GHRH). Like other GHRP-class peptides, it engages hypothalamic arcuate nucleus circuits to potentiate GHRH-driven GH pulses and partially suppress somatostatin inhibitory tone; it was among the first GHRP-class compounds characterized pharmacologically and has been used extensively as a research tool for probing the GH secretory axis. Clinical studies have demonstrated dose-dependent GH release following GHRP-6 administration in human subjects, and the GHRP pharmacological class has been characterized across multiple studies documenting pituitary and hypothalamic mechanisms of action. GHRP-6 is not FDA-approved for any indication; it has been studied as a pharmacological tool and provocative GH stimulation agent but has not been evaluated for safety or efficacy in performance enhancement or muscle building outside research protocols. GHRP-6 dosage in research contexts: studies have used subcutaneous and intravenous doses typically in the range of 100–300 mcg per injection. In research protocols, GHRP-6 is often administered 2–3 times daily — before meals, before training, or before sleep — to leverage the body's natural GH pulse windows. GHRP-6 produces a pronounced appetite stimulation effect (a direct ghrelin-mimetic consequence) that is stronger than what is observed with more selective GHRPs such as ipamorelin; this characteristic is relevant to research contexts studying GH secretion alongside energy intake regulation. GHRP-6 vs GHRP-2: both are non-selective GHRPs producing GH alongside cortisol and prolactin co-stimulation, but GHRP-6 is noted for more pronounced ghrelin-like appetite stimulation, while GHRP-2 produces greater GH output per unit dose in some comparative studies. Neither offers the selectivity profile of ipamorelin, which emerged from subsequent GHRP research specifically to reduce off-target hormonal effects. GHRP-6 is administered by subcutaneous injection following reconstitution with bacteriostatic water. Providers offering GHRP-class secretagogues are listed in the PeptideBase directory.

Ipamorelin binds to the ghrelin receptor (GHSR-1a) and stimulates dose-dependent GH release with a clean hormonal profile. Unlike GHRP-6 or hexarelin, it does not significantly stimulate appetite-related pathways or cortisol secretion at standard research doses. This selectivity makes it a frequently studied peptide for protocols where hormonal side-effect profiles are a consideration.

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and selective growth hormone secretagogue that acts as a ghrelin receptor (GHS-R1a) agonist, valued in research for its selectivity for GH release with minimal concurrent stimulation of cortisol, prolactin, or ACTH compared to earlier GH-releasing peptides such as GHRP-2 and GHRP-6. Ipamorelin stimulates pulsatile GH secretion from pituitary somatotrophs through ghrelin receptor signaling; its selective endocrine profile was characterized preclinically and distinguishes it from less selective GHRPs, making it a widely used tool compound in GH secretagogue research and the subject of exploratory clinical development for GI motility applications. The only indexed Phase II human trial of ipamorelin examined its effects on postoperative ileus in bowel resection patients, demonstrating GI motility improvements consistent with its enteric GHS-R1a activity; no published human data addresses its effects on GH secretion, body composition, or performance outcomes in the contexts for which it is commonly used as a research compound. Ipamorelin has no FDA approval for any indication; it is a research compound with well-characterized preclinical pharmacology and a single published human trial in a GI context, and claims regarding its use for muscle gain, fat loss, or anti-aging purposes are not supported by published clinical evidence. Ipamorelin is frequently studied in combination with CJC-1295 (a GHRH analogue), with the rationale that CJC-1295 extends the GHRH pulse window while ipamorelin provides selective GHS-R1a stimulation without additional cortisol or prolactin burden. The CJC-1295 ipamorelin combination is among the most commonly researched GH secretagogue pairings in both the research literature and in compounded clinical protocols, and both compounds are available through telehealth providers and compounding pharmacies in the PeptideBase directory. A triple combination of sermorelin, ipamorelin, and CJC-1295 has also been explored in research contexts as a multi-pathway approach to GH axis support, though no published human trial evidence supports this specific combination. Ipamorelin's side effect profile in preclinical and limited clinical research is considered favorable relative to earlier GHRPs. Unlike GHRP-2 and GHRP-6, which produce dose-dependent elevations in cortisol, prolactin, and ACTH, ipamorelin selectively stimulates GH release with minimal effect on these hormones at standard research doses — its selectivity was a primary design objective in its development. Commonly reported observations in research contexts include transient water retention (attributed to IGF-1-mediated sodium reabsorption at higher doses), mild injection-site discomfort, and occasionally headache or flushing shortly after administration, consistent with the acute GH pulse. Long-term use considerations include potential receptor desensitization with continuous daily dosing, which is why cycling protocols (e.g., 5 days on, 2 days off, or monthly off-cycles) are common in research designs. At doses substantially exceeding research norms, GH-class effects such as peripheral paresthesia, joint stiffness, and carpal tunnel-type symptoms have been observed — consistent with GH-excess effects across secretagogue and exogenous HGH literature. Ipamorelin's long-term safety profile in humans has not been established through controlled clinical trials; all available safety observations derive from preclinical studies and the single published Phase II GI motility trial, which was short-duration and not designed to assess endocrine safety endpoints.